E. Yekeduz Et Al. , "The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study," JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.148, no.12, pp.3537-3546, 2022
Yekeduz, E. Et Al. 2022. The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.148, no.12 , 3537-3546.
Yekeduz, E., Tural, D., Erturk, I., Karakaya, S., EROL, C., Ercelep, O., ... Arslan, C.(2022). The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.148, no.12, 3537-3546.
Yekeduz, EMRE Et Al. "The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study," JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.148, no.12, 3537-3546, 2022
Yekeduz, EMRE Et Al. "The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.148, no.12, pp.3537-3546, 2022
Yekeduz, E. Et Al. (2022) . "The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.148, no.12, pp.3537-3546.
@article{article, author={EMRE YEKEDÜZ Et Al. }, title={The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study}, journal={JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY}, year=2022, pages={3537-3546} }